ISRCTN52157196 https://doi.org/10.1186/ISRCTN52157196

MYELOMA VIIIth trial

Submission date 25/10/2000	**Recruitment status** No longer recruiting	[ ] Prospectively registered [ ] Protocol
Registration date 25/10/2000	**Overall study status** Completed	[ ] Statistical analysis plan [ ] Results
Last Edited 27/09/2019	**Condition category** Cancer	[ ] Individual participant data [ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Mark Drayson

Contact details
Department of Immunology
Medical School
University of Birmingham
Vincent Drive
Birmingham
United Kingdom
B15 2TT
-
m.t.drayson@bham.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
G8003737 expired Oct 99

Study information

Scientific Title
MYELOMA VIIIth trial

Acronym
MYELOMA VIIIth trial

Study objectives
To compare, for survival, the induction of first plateau phase in previously untreated patients with multiple myeloma, the efficacy of the above two treatments

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Other

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Leukaemia

Interventions
All patients receive three courses of ABCM. They are then randomised to continue with ABCM or to change to oral weekly cyclophosphamide.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Cyclophosphamide and ABCM

Primary outcome measure
1. Survival
2. Obtaining plateau (stable disease with no more than minimal symptoms)
3. Quality of life

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/11/1993

Completion date
01/11/2000

Eligibility

Key inclusion criteria
1. Greater than 65 years old and less than 75 years old
2. Myeloma
3. No previous cytotoxic therapy
4. Netrophil count greater than or equal to 1.3 x 10^9/l
5. Platelet count greater than or equal to 75 x 10^9/L
6. Able to tolerate 3 l of fluid per day
7. Apyrexial
8. Free from infection
9. Informed consent

Participant type(s)
Patient

Age group
Senior

Sex
Not Specified

Target number of participants
1000

Key exclusion criteria
Patients with equivocal myelomatosis

Date of first enrolment
01/11/1993

Date of final enrolment
01/11/2000

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Department of Immunology
Birmingham
United Kingdom
B15 2TT

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration